Literature DB >> 21042225

Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy.

Cécile Berthelot1, Olivier Morel, Sylvie Girault, Véronique Verrièle, Anne-Lise Poirier, Julien Moroch, Yvan Boucher, Jean-Jacques Le Jeune, Gérard Lorimier.   

Abstract

BACKGROUND: Peritoneal carcinomatosis (PC) is associated with a very poor prognosis. Complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has been shown to improve survival rates of PC. However, this treatment is beneficial for patients if the complete cytoreductive surgery is macroscopically completed before implementing hyperthermic intraperitoneal chemotherapy. Even so, a strict selection of patients is of fundamental importance because of the invasive nature of the intervention. The aim of this study was to assess the performance of FDG-PET/CT examinations for the diagnosis and evaluation of the extent of PC.
METHODS: A retrospective analysis was conducted on 28 consecutive patients with suspected PC, scheduled for a complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and who underwent an FDG-PET/CT examination. We compared the results of PET examinations with histological and intraoperative findings. The extent of PC was assessed precisely using a simplified 'peritoneal cancer index', within the three modalities (PET, surgery and histology).
RESULTS: Of 28 patients, 23 had histological PC. The sensitivity and specificity of the PET examination for the diagnosis of PC were, respectively, 82 and 100%. Even if the extent of PC was underestimated by PET, there was a good correlation when compared with histology and intraoperative results.
CONCLUSION: PET presented a good performance level in the diagnosis and evaluation of the extent of PC. PET/CT examinations could be useful to avoid unnecessary surgery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21042225     DOI: 10.1097/MNM.0b013e328340e730

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

Review 1.  Current treatment options for colon cancer peritoneal carcinomatosis.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

Review 2.  Diagnostic accuracy of 18F-FDG PET/CT for detection of peritoneal carcinomatosis; a systematic review and meta-analysis.

Authors:  Seong-Jang Kim; Sang-Woo Lee
Journal:  Br J Radiol       Date:  2017-11-21       Impact factor: 3.039

Review 3.  Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer.

Authors:  Pompiliu Piso; Dirk Arnold
Journal:  Dtsch Arztebl Int       Date:  2011-11-25       Impact factor: 5.594

4.  Localized peritoneal carcinomatosis mimicking an irreducible left inguinal hernia.

Authors:  N C Buchs; A L A Bloemendaal; R J Guy
Journal:  Ann R Coll Surg Engl       Date:  2016-03       Impact factor: 1.891

5.  Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy.

Authors:  Michael Soussan; Gaëtan Des Guetz; Vincent Barrau; Vanessa Aflalo-Hazan; Gabriel Pop; Ziad Mehanna; Edmond Rust; Thomas Aparicio; Richard Douard; Robert Benamouzig; Philippe Wind; Véronique Eder
Journal:  Eur Radiol       Date:  2012-02-24       Impact factor: 5.315

Review 6.  Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research.

Authors:  Foteini Stefania Koumpa; Diamantis Xylas; Maciej Konopka; Dieter Galea; Kirill Veselkov; Anthony Antoniou; Akash Mehta; Reza Mirnezami
Journal:  Gastroenterol Res Pract       Date:  2019-04-01       Impact factor: 2.260

7.  Combining Diffusion-Weighted Imaging and T2-Weighted Imaging to Delineate Tumorous Tissue in Peritoneal Carcinomatosis: A Comparative Study with 18F-Fluoro-Deoxyglucose Positron Emission Tomography with Computed Tomography (FDG PET/CT).

Authors:  Qing Wu; Xiufang Xu
Journal:  Med Sci Monit       Date:  2022-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.